(1 - 12 from 24
)
Teva to buy U.S. drug developer …
www.reuters.com
· Teva to buy U.S. drug developer Auspex Pharma for $3.5 billion Bernstein analyst Aaron Gal said the acquisition was a good strategic fit for Teva ...
Aaron Gal | Benzinga
www.benzinga.com
Biotech investors may have noticed that the first quarter of the year is a bit sluggish for drug sales. They aren’t imagining things, according to Bernstein analyst ...
Teva Tumbles, Twitter Soars as Market Seeks Direction (Link ...
cryptonewsagency.com
... revenue recovery likely coming down, the argument for mid-term (2-4 years) recovery got tougher," writes Bernstein analyst Aaron Gal. Tyson Foods (TSN) has climbed 4.9% to $ after reporting better-than-expected first-quarter earnings and sales and offering consensus-topping full-year guidance .
And Now, Gastric Surgery for Kids - Bloomberg
www.bloomberg.com
Sanford C. Bernstein analyst Aaron Gal says approval for children could increase Lap-Band sales by as much as $20 million a year.
sorted by relevance / date